Galectin Therapeutics INC (GALT) — SEC Filings

Overview

Galectin Therapeutics INC (GALT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 13, 2026: Galectin Therapeutics Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 13, 2026. The filing relates to registration number 333-294782 and was accepted with accession number 9999999995-26-001150. The company's mailing and business address is 4960 Peachtree

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 2 mixed. The dominant filing sentiment for Galectin Therapeutics INC is neutral.

Filing Type Overview

Galectin Therapeutics INC (GALT) has filed 1 EFFECT, 18 8-K, 3 10-K, 5 10-Q, 2 DEF 14A with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Galectin Therapeutics SEC Filing Effectiveness — EFFECT · Apr 13, 2026 Risk: low
  Galectin Therapeutics Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 13, 2026. The filing relates to registration
• Galectin Therapeutics Files 8-K on Financials — 8-K · Mar 31, 2026 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on March 31, 2026, reporting on its results of operations and financial condition for the period ending March 31, 2026.
• GALT's Belapectin Shows Promise in MASH Cirrhosis, Varices Reduced — 10-K · Mar 31, 2026 Risk: high
  GALECTIN THERAPEUTICS INC. (GALT) reported top-line results for its NAVIGATE Phase 2b/3 clinical trial in December 2024, evaluating belapectin for the preventio
• 8-K Filing — 8-K · Dec 19, 2025
• 8-K Filing — 8-K · Dec 8, 2025
• 8-K Filing — 8-K · Dec 3, 2025
• Galectin Therapeutics Narrows Loss Amidst R&D Cut, Bolstered by Insider Loan — 10-Q · Nov 14, 2025 Risk: high
  GALECTIN THERAPEUTICS INC. reported a net loss of $8.184 million for the three months ended September 30, 2025, an improvement from a net loss of $11.220 millio
• 8-K Filing — 8-K · Nov 10, 2025
• Galectin Therapeutics Goes Virtual for 2025 Annual Meeting — DEF 14A · Oct 22, 2025 Risk: low
  Galectin Therapeutics Inc. is holding its 2025 Annual Meeting virtually on December 3, 2025, to elect eleven directors, approve executive compensation on a non-
• Galectin Therapeutics Files 8-K — 8-K · Sep 8, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on September 8, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Galectin Therapeutics Narrows Losses Amid R&D Cuts, Secures New Funding — 10-Q · Aug 14, 2025 Risk: high
  GALECTIN THERAPEUTICS INC. reported a net loss of $7.521 million for the three months ended June 30, 2025, a significant improvement from the $12.371 million ne
• Galectin Therapeutics Files 8-K with Material Agreement, Director Changes — 8-K · Jul 9, 2025 Risk: medium
  Galectin Therapeutics Inc. announced on July 8, 2025, the entry into a material definitive agreement and changes in its board of directors and officer compensat
• Galectin Therapeutics Files 8-K — 8-K · Jun 16, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on June 16, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly k
• Galectin Therapeutics Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition, as well as filing financial statements
• Galectin Therapeutics Files 8-K — 8-K · May 12, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on May 12, 2025, reporting on various events including Regulation FD Disclosures, Other Events, and Financial Statements
• Galectin Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Galectin Therapeutics Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Pro Phar
• Galectin Therapeutics Files 8-K — 8-K · Mar 5, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on March 5, 2025, reporting on its current activities. The filing primarily serves as a notification of information and
• Galectin Therapeutics Files 8-K — 8-K · Feb 18, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on February 18, 2025, reporting other events and financial statements. The company, formerly known as PRO PHARMACEUTICAL
• Galectin Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jan 28, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on January 28, 2025, reporting a submission of matters to a vote of security holders on January 23, 2025. The company, f
• Galectin Therapeutics Files 8-K — 8-K · Jan 23, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on January 23, 2025, reporting on financial statements and exhibits. The company, formerly known as Pro Pharmaceuticals
• Galectin Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly k
• Galectin Therapeutics Files 8-K — 8-K · Dec 20, 2024 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The company, formerly known as Pro Pharmaceutical
• Galectin Therapeutics Files 2024 Proxy Statement — DEF 14A · Dec 3, 2024 Risk: low
  Galectin Therapeutics Inc. filed a DEF 14A proxy statement on December 3, 2024, for its annual meeting scheduled for January 23, 2025. The company, formerly kno
• Galectin Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Galectin Therapeutics Inc. filed its Q3 2024 10-Q report on November 14, 2024, detailing its financial performance for the period ending September 30, 2024. The
• Galectin Therapeutics Files 8-K — 8-K · Sep 9, 2024 Risk: low
  Galectin Therapeutics Inc. filed an 8-K on September 9, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Galectin Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Galectin Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial condition and business operations. The company, former
• Galectin Therapeutics Announces Leadership Changes — 8-K · Aug 1, 2024 Risk: medium
  Galectin Therapeutics Inc. announced on July 26, 2024, the departure of its Chief Medical Officer, Dr. Richard A. Baker. The company also reported the election
• Galectin Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  GALECTIN THERAPEUTICS INC (GALT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Galectin Therapeutics Inc. filed a 10-Q report for the period end
• Galectin Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: medium
  GALECTIN THERAPEUTICS INC (GALT) filed a Annual Report (10-K) with the SEC on March 29, 2024. Galectin Therapeutics Inc. filed its 2023 Form 10-K on March 29, 2

Risk Profile

Risk Assessment: Of GALT's 25 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Galectin Therapeutics INC's most recent 10-K filing (Mar 31, 2026):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Richard Uihlein
• Joel Lewis
• Jack W. Callicutt
• Dr. Richard A. Baker
• Dr. Steven M. Altschuler
• Mr. David M. S. Johnson

Industry Context

Galectin Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing therapies for fibrotic diseases and cancer. The MASH market is rapidly evolving with significant unmet needs, attracting substantial investment and numerous drug candidates. Similarly, the oncology space, particularly for head and neck cancer, is characterized by advancements in immunotherapy and combination treatments.

Top Tags

financials (7) · 8-K (4) · corporate-filing (4) · Biotechnology (3) · corporate-governance (3) · 10-Q (3) · 8-k (2) · Clinical Stage (2) · Going Concern (2) · Related Party Transactions (2)

Key Numbers

• Registration File Number: 333-294782 — Identifies the specific registration statement that has become effective.
• Filing Acceptance Date: 2026-04-13 — Date the SEC accepted the filing.
• Effectiveness Date: 2026-04-10 — Date the registration statement became effective.
• Aggregate market value of common equity held by non-affiliates: $109 million — As of June 30, 2025
• Shares outstanding of common stock: 65,827,448 — As of March 2, 2026
• Patients randomized in NAVIGATE trial: 357 — Completed in February 2023
• Reduced incidence of varices in belapectin 2 mg/kg dose group vs placebo: 43.2% — NAVIGATE ITT population (N=355)
• Reduced incidence of varices in belapectin 2 mg/kg dose group: 49.3% — NAVIGATE per-protocol population (n=287), p-value < 0.05
• Significantly reduced incidence of varices in U.S. patients treated with belapectin 2 mg: 68.1% — NAVIGATE U.S. completer patients (n=186), p=0.02
• Cash and Cash Equivalents: $11.525M — Decreased from $15.120M at Dec 31, 2024, highlighting liquidity concerns.
• Net Loss (9 months): $25.336M — Improved from $35.080M in 2024, but still substantial for a no-revenue company.
• R&D Expenses (9 months): $12.357M — Significantly reduced from $25.462M in 2024, impacting future pipeline development.
• Total Liabilities: $136.445M — Increased from $120.565M at Dec 31, 2024, driven by related-party debt.
• New Line of Credit: $10M — Provided by Chairman Richard Uihlein on July 8, 2025, crucial for short-term funding.
• Common Shares Outstanding: 64,472,792 — As of November 7, 2025, indicating potential dilution from convertible instruments.

Frequently Asked Questions